Express Pharma

Suven Life Sciences gets patents from neuro-degenerative drugs

1

Receives product patents from Europe and Eurasia

Suven Life Sciences has been granted one product patent from Europe and two product patents from Eurasia for a drug used in the treatment of neuro-degenerative diseases. In a BSE filing, Suven Life said it has been granted “one product patent from Europe and two product patents from Eurasia corresponding to new chemical entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases.’’

The patents are valid through 2029, 2030 and 2031, respectively, the company added.

Venkat Jasti, CEO, Suven Life Sciences said, “We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”

With these clearances, Suven has 21 granted patents from Europe and 19 from Eurasia.

“These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II,” Suven said.

Comments are closed.